Sponsor:
Daniel Merenstein
Code:
NCT06076304
Conditions
Sinus Infection
Acute Sinusitis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
amoxicillin/clavulanate potassium
Placebo
Budesonide nasal spray
Brief summary:
Conditions
Sinus Infection
Acute Sinusitis
Study ID
NCT06076304
Start date
Nov 21, 2023
Status verified date
Feb, 2026
Completion date
Dec, 2028
Anticipated
Primary completion date
Oct, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
3720 participants
Anticipated
Allocation
Randomized
Intervention Model
Factorial
Primary purpose
Treatment
Arms
active comparator: antibiotic
placebo comparator: placebo antibiotic
active comparator: antibiotic plus intranasal corticosteroid
other: placebo antibiotic plus intranasal corticosteroid
Interventions
amoxicillin/clavulanate potassium
Placebo
Budesonide nasal spray
Primary outcome measure
Central contacts
Locations
University of California, Los Angeles
Recruiting
Los Angeles, California, United States, 90095
Principal Investigator:
Derjung Mimi Tarn, MD, PhD
Georgetown University Medical Center
Recruiting
Washington D.C., District of Columbia, United States, 20007
Principal Investigator:
Daniel Merenstein, MD
Penn State College of Medicine
Recruiting
Hershey, Pennsylvania, United States, 17033
Principal Investigator:
David Rabago, MD
Virginia Commonwealth University
Recruiting
Richmond, Virginia, United States, 23219
Principal Investigator:
Alexander Krist, MD, MPH
University of Washington
Recruiting
Seattle, Washington, United States, 98195
Principal Investigator:
Sebastian Tong, MD, MPH
University of Wisconsin-Madison
Recruiting
Madison, Wisconsin, United States, 53705
Principal Investigator:
Bruce Barrett, MD, PhD
Sponsor
Daniel Merenstein
Last update posted
Mar 3, 2026
Last verified
Feb, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Daniel Merenstein on 2026-03-03.